Engineering M13 bacteriophage platforms for cancer therapy applications
Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2015. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 46-48). === Two novel schemes for engineering M13 bacteriophage for application in the diagnosis, imaging and trea...
Main Author: | |
---|---|
Other Authors: | |
Format: | Others |
Language: | English |
Published: |
Massachusetts Institute of Technology
2016
|
Subjects: | |
Online Access: | http://hdl.handle.net/1721.1/103838 |
id |
ndltd-MIT-oai-dspace.mit.edu-1721.1-103838 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-MIT-oai-dspace.mit.edu-1721.1-1038382019-05-02T15:39:16Z Engineering M13 bacteriophage platforms for cancer therapy applications Tsedev, Uyanga Angela M. Belcher and Alan J. Grodzinsky. Massachusetts Institute of Technology. Department of Mechanical Engineering. Massachusetts Institute of Technology. Department of Mechanical Engineering. Mechanical Engineering. Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2015. Cataloged from PDF version of thesis. Includes bibliographical references (pages 46-48). Two novel schemes for engineering M13 bacteriophage for application in the diagnosis, imaging and treatment of human tumors are proposed. Firstly, by exploiting the uniquely malleable biology of the M13 filamentous phage, we have engineered filamentous phages of shorter lengths by constructing our own set of small viral ssDNA that are packaged by M13 capsid proteins. These 'inho' phages can be sized to ~50nm and above in length. The small phage retains the M13 major and minor coat proteins which have previously been manipulated to serve as tethers to carry various therapy and imaging agents and target specific cancer sites. Now with the ability to control the aspect ratio of these rigid, rod-like phages we can further improve on M13 based cancer detection by optimizing for phage blood circulation and tumor extravasation. Secondly, we have added to our cancer targeting M13 platform collection by cloning for chlorotoxin display on the tail p3 capsid protein of M13. Chlorotoxin can induce passage across blood-brain barrier, targets for cancer cells, and specifically internalizes to glioma cells. Expression of chlorotoxin on M13 will allow us to capitalize on its strong affinity for tumors of neuroectodermal origin and expand the M13 therapy and imaging platform to tumor masses in the brain. by Uyanga Tsedev. S.M. 2016-08-02T20:07:16Z 2016-08-02T20:07:16Z 2015 2015 Thesis http://hdl.handle.net/1721.1/103838 953868616 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 48 pages application/pdf Massachusetts Institute of Technology |
collection |
NDLTD |
language |
English |
format |
Others
|
sources |
NDLTD |
topic |
Mechanical Engineering. |
spellingShingle |
Mechanical Engineering. Tsedev, Uyanga Engineering M13 bacteriophage platforms for cancer therapy applications |
description |
Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2015. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 46-48). === Two novel schemes for engineering M13 bacteriophage for application in the diagnosis, imaging and treatment of human tumors are proposed. Firstly, by exploiting the uniquely malleable biology of the M13 filamentous phage, we have engineered filamentous phages of shorter lengths by constructing our own set of small viral ssDNA that are packaged by M13 capsid proteins. These 'inho' phages can be sized to ~50nm and above in length. The small phage retains the M13 major and minor coat proteins which have previously been manipulated to serve as tethers to carry various therapy and imaging agents and target specific cancer sites. Now with the ability to control the aspect ratio of these rigid, rod-like phages we can further improve on M13 based cancer detection by optimizing for phage blood circulation and tumor extravasation. Secondly, we have added to our cancer targeting M13 platform collection by cloning for chlorotoxin display on the tail p3 capsid protein of M13. Chlorotoxin can induce passage across blood-brain barrier, targets for cancer cells, and specifically internalizes to glioma cells. Expression of chlorotoxin on M13 will allow us to capitalize on its strong affinity for tumors of neuroectodermal origin and expand the M13 therapy and imaging platform to tumor masses in the brain. === by Uyanga Tsedev. === S.M. |
author2 |
Angela M. Belcher and Alan J. Grodzinsky. |
author_facet |
Angela M. Belcher and Alan J. Grodzinsky. Tsedev, Uyanga |
author |
Tsedev, Uyanga |
author_sort |
Tsedev, Uyanga |
title |
Engineering M13 bacteriophage platforms for cancer therapy applications |
title_short |
Engineering M13 bacteriophage platforms for cancer therapy applications |
title_full |
Engineering M13 bacteriophage platforms for cancer therapy applications |
title_fullStr |
Engineering M13 bacteriophage platforms for cancer therapy applications |
title_full_unstemmed |
Engineering M13 bacteriophage platforms for cancer therapy applications |
title_sort |
engineering m13 bacteriophage platforms for cancer therapy applications |
publisher |
Massachusetts Institute of Technology |
publishDate |
2016 |
url |
http://hdl.handle.net/1721.1/103838 |
work_keys_str_mv |
AT tsedevuyanga engineeringm13bacteriophageplatformsforcancertherapyapplications |
_version_ |
1719025366854533120 |